Skip to main content
. 2020 Jan 16;111(3):849–856. doi: 10.1111/cas.14289

Figure 3.

Figure 3

Dasatinib, an SRC family inhibitor, enables the resistance to neratinib to be overcome. A, MTS assay to assess the effect of neratinib alone, dasatinib alone and the combination of neratinib plus dasatinib on (i) BT‐474, BT‐474‐NRS, BT‐474‐NRS2, (ii) H2170 and H2170‐NRH. The cells were treated with the drugs for 72 h. The assay was repeated three times. Data are shown as mean ± standard error. B, Effect of neratinib alone, dasatinib alone and the combination of neratinib plus dasatinib on protein phosphorylation in (i) BT‐474, BT‐474‐NRS, BT‐474‐NRS2, (ii) H2170 and H2170‐NRH. The cells were treated with the drugs for 2 h. C, Apoptosis assay by detection of PARP cleavage in (i) BT‐474, BT‐474‐NRS, BT‐474‐NRS2, (ii) H2170 and H2170‐NRH. The cells were treated with neratinib alone, dasatinib alone or the combination of neratinib plus dasatinib for 48 h. D, Growth of BT‐474‐NRS2 in BALB/c nude mice. The mice were given neratinib (10 mg/kg) alone, dasatinib (15 mg/kg) alone or the combination of neratinib plus dasatinib by oral gavage five times a week. Data are shown as mean ± SE (n = 6)